# US 8,569,346 B1 · Thiazoline ring compounds as botulinum antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,569,346 B1
- Document ID: US8569346B1
- Status: Granted
- Kind: B1
- Application number: 12/904,360
- Filed: 2010-10-14
- Granted: 2013-10-29
- Earliest claimed: 2009-10-14
- Assignees: BioMadison, Inc.
- Applicants: Füsûn N. Zeytin; Ward Tucker
- Inventors: Füsûn N. Zeytin; Ward Tucker
- Web page: https://patentgrep.com/patent/US8569346B1

## CPC

- A61K 31/433: Thidiazoles
- A61K 31/425: Thiazoles
- A61K 31/426: 1,3-Thiazoles
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Compositions and methods for inhibiting BoNT protease activity are presented. In most preferred aspects, inhibitors comprise a thiol reactive group, a zinc binding group, a redox active group, an alkylating group, and/or an electrophilic Michael addition acceptor group. Particularly preferred inhibitors include an isothiazolone ring, a thiadiazolidine dione ring, a (hydro)quinone ring, an iminophenol group, and/or a hydrazonophenol group, and inhibit BoNT/A at μM and sub-μM concentrations.

## Claims

### Claim 1

A method of inhibiting BoNT-A light chain activity comprising a step of contacting the BoNT-A light chain with a compound having a structure according to Formula 1:
wherein Y is S; R2 is ═O; R1 is an optionally substituted alkyl or aryl; R3, and R4 are independently H, alkyl, alkenyl, alkaryl, aryl, heteroalkyl, or heteroaryl, wherein each of R3 and R4 may be optionally substituted with one or more substituents, wherein R3 and R4 may optionally form a ring, which may be a heterocyclic ring, and wherein the heterocyclic ring that includes N and Y in Formula I optionally has one or more double bonds.

### Claim 2 (depends on 1)

The method of claim 1 wherein the step of contacting comprises oral administration to or injection of the compound into a subject affected with BoNT-A.

### Claim 3 (depends on 2)

The method of claim 2 wherein administration or injection of the compound is performed as prophylactic measure.